# Eli Lilly and Company: Phase 1 study completed, 121 enrolled (Healthy, Type 1 Diabetes Mellitus)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | Eli Lilly and Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) |
| NCT ID | NCT06280703 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Healthy; Type 1 Diabetes Mellitus |
| Intervention types | drug |
| Target enrollment | 121 |
| Site countries | Germany |
| Posted | 2024-02-28 |
| Planned start | 2024-05-15 |
| Event | Completed |
| Event date | 2026-10-03 |
| Last update posted | 2026-10-06 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- 121 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06280703). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.